Langley RG2727. Langley RG, Lebwohl M, Krueger GG, Szapary PO4, Wasfi Y, Chan D, Hsu M, You Y, Poulin Y, Korman N, Prinz JC, Reich K; PHOENIX 2 Investigators. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371-83. doi: 10.1111/bjd.13469. PubMed PMID: 25307931 https://doi.org/10.1111/bjd.13469...
|
45mg |
244 weeks |
|
76.5 |
50 |
|
|
|
Langley RG2727. Langley RG, Lebwohl M, Krueger GG, Szapary PO4, Wasfi Y, Chan D, Hsu M, You Y, Poulin Y, Korman N, Prinz JC, Reich K; PHOENIX 2 Investigators. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol. 2015;172(5):1371-83. doi: 10.1111/bjd.13469. PubMed PMID: 25307931 https://doi.org/10.1111/bjd.13469...
|
90mg |
244 weeks |
|
78.6 |
55.5 |
|
|
|
Kimball AB2828. Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB; PHOENIX 1 Investigators. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1535-45. PubMed PMID: 23279003.–3131. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17;371(9625):1665-74. PubMed PMID: 18486739.
|
45mg |
12 weeks |
|
|
|
|
|
47.2 |
Kimball AB2828. Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB; PHOENIX 1 Investigators. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1535-45. PubMed PMID: 23279003.–3131. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, Li S, Dooley LT, Gordon KB; PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008 May 17;371(9625):1665-74. PubMed PMID: 18486739.
|
90mg |
12 weeks |
|
|
|
|
|
46.4 |
Reich K3232. Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, Guenther L, Langley RG. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat. 2011 Dec;22(6):337-47. PubMed PMID: 21034290.–3535. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008 May 17;371(9625):1675-84. PubMed PMID: 18486740.
|
45mg |
12 weeks |
73 |
63 |
41.6 |
18.1 |
72.6 |
48.9 |
Reich K3232. Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, Guenther L, Langley RG. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2. J Dermatolog Treat. 2011 Dec;22(6):337-47. PubMed PMID: 21034290.–3535. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, Yeilding N, Guzzo C, Hsu MC, Wang Y, Li S, Dooley LT, Reich K; PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008 May 17;371(9625):1675-84. PubMed PMID: 18486740.
|
90mg |
12 weeks |
78.7 |
72 |
50.2 |
18.2 |
71.4 |
54.6 |
Nakagawa H3636. Nakagawa H, Schenkel B, Kato M, Kato T, Igarashi A; Japanese Ustekinumab Study Group. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial. J Dermatol. 2012 Sep;39(9):761-9. PubMed PMID: 22409383.,3737. Igarashi A, Kato T, Kato M, Song M, Nakagawa H; Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012 Mar;39(3):242-52. PubMed PMID: 21955098.
|
45mg |
12 weeks |
69.9 |
52.9 |
29.6 |
|
|
58.1 |
Nakagawa H3636. Nakagawa H, Schenkel B, Kato M, Kato T, Igarashi A; Japanese Ustekinumab Study Group. Impact of ustekinumab on health-related quality of life in Japanese patients with moderate-to-severe plaque psoriasis: results from a randomized, double-blind, placebo-controlled phase 2 / 3 trial. J Dermatol. 2012 Sep;39(9):761-9. PubMed PMID: 22409383.,3737. Igarashi A, Kato T, Kato M, Song M, Nakagawa H; Japanese Ustekinumab Study Group. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol. 2012 Mar;39(3):242-52. PubMed PMID: 21955098.
|
90mg |
12 weeks |
71 |
61.2 |
40.3 |
|
|
54.1 |
Tsai TF3838. Tsai TF, Ho JC, Song M, Szapary P, Guzzo C, Shen YK, Li S, Kim KJ, Kim TY, Choi JH, Youn JI; PEARL Investigators. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011 Sep;63(3):154-63. PubMed PMID: 21741220.
|
45mg |
12 weeks |
|
62.2 |
|
|
62.2 |
|